Muscle Spasticity Market Report 2026

The muscle spasticity market size has grown strongly in recent years. It will grow from $4.55 billion in 2025 to $4.96 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rise in neurological injury cases, increased prevalence of spinal cord disorders, growth in post-stroke complications, early use of oral muscle relaxants, limited access to targeted therapies.

The muscle spasticity market size is expected to see strong growth in the next few years. It will grow to $6.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to advancement in drug delivery systems, increasing adoption of botox-based treatments, growth in home-based rehabilitation solutions, rising investment in neurological care, expanding clinical research in spasticity therapies. Major trends in the forecast period include increasing preference for botulinum toxin treatments, rising adoption of intrathecal baclofen therapy, growing demand for oral muscle relaxants, expansion in rehabilitation and physical therapy programs, increasing focus on personalized spasticity management.

The increasing prevalence of musculoskeletal disorders is expected to drive the growth of the muscle spasticity market. Musculoskeletal disorders, which affect muscles, bones, and joints, often cause pain, stiffness, and limited mobility. Factors such as aging populations, sedentary lifestyles, and rising chronic conditions have contributed to this increase. Muscle spasticity treatments aim to relieve these symptoms, improve mobility, prevent complications, and enhance overall quality of life and functional abilities. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, 18.4% of people aged 16 and over reported having a long-term musculoskeletal condition in 2023, slightly up from 17.6% in 2022, with higher prevalence among females (20.9%) than males (15.8%). Therefore, the rising incidence of musculoskeletal disorders is propelling the muscle spasticity market.

Major companies in the muscle spasticity market are focusing on developing novel oral muscle-relaxant formulations to improve dosing flexibility, enhance patient adherence, and aid individuals who struggle with traditional solid-dose therapies. These formulations, such as liquid suspensions, enable precise dosing and better tolerability for patients. For example, in April 2024, ANI Pharmaceuticals, a US-based pharmaceutical manufacturer, launched baclofen oral suspension, a generic version of Fleqsuvy, which is used to treat muscle spasms caused by conditions such as multiple sclerosis and spinal cord injuries by relaxing muscles effectively.

In November 2025, CNX Therapeutics, a UK-based specialty pharmaceutical company, acquired Sativex (nabiximols) from Jazz Pharmaceuticals plc for an undisclosed amount. This acquisition strengthens CNX’s central nervous system (CNS) and neurology portfolio by adding a plant-derived spasticity treatment for moderate to severe muscle spasticity in multiple sclerosis. Jazz Pharmaceuticals plc, an Ireland-based biopharmaceutical company, developed and commercialized Sativex, which provides an established therapeutic option for patients needing targeted spasticity management.

Major companies operating in the muscle spasticity market are F. Hoffmann‑La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Teva Pharmaceutical Industries Ltd., Ipsen Pharma, Endo Pharmaceuticals Inc., Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Revance Therapeutics Inc., Acorda Therapeutics Inc., Zydus Cadila, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., UCB Pharma S.A., Jazz Pharmaceuticals plc, Daiichi Sankyo Company Limited, GlaxoSmithKline plc, InMed Pharmaceuticals Inc., MediciNova Inc., Genentech Inc., Beximco Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited.

North America was the largest region in the muscle spasticity market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscle spasticity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients, injectable formulations, and medical devices have raised overall treatment and procurement costs across the muscle spasticity market, particularly impacting hospitals and rehabilitation centers reliant on imported botulinum toxin products and intrathecal pump systems. Regions dependent on international supply chains face delays and higher distribution expenses. However, tariffs have encouraged local production of muscle relaxants and stimulated innovation in affordable therapeutic alternatives, partially mitigating long-term cost pressures.

The muscle spasticity market research report is one of a series of new reports that provides muscle spasticity market statistics, including muscle spasticity industry global market size, regional shares, competitors with a muscle spasticity market share, detailed muscle spasticity market segments, market trends and opportunities, and any further data you may need to thrive in the muscle spasticity industry. This muscle spasticity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Muscle spasticity is a condition marked by an abnormal increase in muscle tone or stiffness, which can impede movement and speech. It often results from damage to the brain or spinal cord that regulates voluntary muscle activity.

The main drugs used in the muscle spasticity market include baclofen, botulinum toxin, diazepam, dantrolene sodium, and others. These medications are administered through various routes, such as oral and intramuscular, and are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

The muscle spasticity market consists of revenues earned by entities by providing services such as pharmaceutical treatments, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle spasticity market also includes sales of tizanidine, gabapentin, and pregabalin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.